Genomics
PrivateThe #2 epigenetic HBV silencer — same mechanism, same indication, ~12 months behind Tune, on a merger-of-necessity balance sheet; a clean late-2026 readout makes it a credible M&A/IPO asset, a durability miss kills the whole modality. WATCHING until the first human cccDNA-silencing data prints.
Research
The verdict
The #2 epigenetic HBV silencer — same mechanism, same indication, ~12 months behind Tune, on a merger-of-necessity balance sheet; a clean late-2026 readout makes it a credible M&A/IPO asset, a durability miss kills the whole modality. WATCHING until the first human cccDNA-silencing data prints.
nChroma Bio is a private, clinical-stage genetic-medicines company in Boston (201 Brookline Avenue) built to do one thing the genome-editing field has spent a decade struggling with: turn a disease gene off durably, without cutting the DNA, and actually get the machine to the right tissue. It was formed in December 2024 by merging two venture-backed startups that were each missing the other's half — Chroma Medicine (the epigenetic "cargo" — editors that write repressive marks onto DNA) and Nvelop Therapeutics (the "delivery" — programmable non-viral vehicles).
What the product is. A single-administration epigenetic silencer. The lead asset, CRMA-1001, is a catalytically-inactive Cas9 (dCas9) fused to proprietary epigenetic effector domains that deposit targeted DNA methylation at hepatitis B viral loci — silencing gene expression without double-strand breaks, and hitting both the episomal cccDNA reservoir and integrated HBV DNA. The pitch is a functional cure for chronic hepatitis B (and ultimately HBV/HDV coinfection) from one dose, where the standard of care is lifelong nucleos(t)ide suppression that cures ~1% of patients.
Business model. Pre-revenue, pre-product, single-clinical-asset biotech. There is no P&L — value is the risk-adjusted NPV of CRMA-1001 plus an option on the delivery platform (LNP for liver, engineered virus-like particles / eVLPs for extrahepatic targets). Monetization is the standard genetic-medicine path: dose-escalate → proof-of-concept → partner or sell to large pharma, or IPO into a data catalyst. nChroma is not selling anything; it is spending venture capital to de-risk a binary scientific bet.
Customers / suppliers / competitors (named).
Contract structure. None that bears on revenue — no take-or-pay, no recurring contracts. The only "contracts" are the venture financing terms and (unconfirmed) any platform-delivery collaborations. Capital structure, not commercial structure, is what matters at this stage.
For a pre-clinical-stage drug the "supply chain" is the discovery-to-dose value chain, and naming the actual links exposes where nChroma is and isn't differentiated:
Academic IP (Broad / MIT / Whitehead — CRISPRoff, dCas9-effector domains) → Chroma/nChroma in-house editor engineering → dCas9 + effector-domain payload (mRNA/protein) → delivery formulation: LNP (liver) or eVLP (extrahepatic) → CDMO manufacturing (GMP payload + particle fill-finish) → Phase 1/2 clinical sites (Hong Kong, New Zealand, UK) → chronic-HBV patient.
Chokepoints / single-source dependencies (the analyst's job here is to name them):
Names or it didn't happen: the upstream IP traces to the labs of David Liu, Keith Joung, Jonathan Weissman, Luke Gilbert, Luigi Naldini, Angelo Lombardo (the six academic founders of Chroma). The downstream clinical chain runs through regulators in Hong Kong (first CTA), New Zealand, and the UK — pointedly not the FDA first (see Lens 10/13).
The modality moat (shared, not proprietary). Epigenetic silencing as a class has a genuine advantage over both classical CRISPR and RNA approaches: it modulates expression without double-strand breaks (no genomic-rearrangement / DNA-repair-pathway risk that dogs nuclease editing) yet aims for durability that transient RNA approaches (siRNA, ASO — which require chronic re-dosing) cannot match. That is a real moat for the modality — but nChroma shares it with Tune, Epic Bio, Omega, Moonwalk.
Company-specific moats — and where they're thin:
Bargaining power. Essentially none today — pre-revenue, cash-consuming, one asset, dependent on CDMOs and capital markets. Bargaining power is entirely prospective: it accrues only if CRMA-1001 prints clean human data, at which point the leverage flips (pharma needs the asset more than nChroma needs any single partner). Right now the company is the price-taker on capital and manufacturing.
Verdict on the moat: the durable moat is IP + founding science + the dual platform; the lead asset's moat is weak (commoditized LNP-to-liver delivery, a faster rival in the exact same indication). The platform is the bull case; the lead asset is the de-risking event.
No revenue → no commercial segments. `` The operating-company segment lens does not apply; the meaningful "segmentation" of a single-asset clinical-stage private is by program and by clinical geography:
By program (the real "segment" mix — 100% concentrated):
| Segment | Stage | Share of value |
|---|---|---|
| CRMA-1001 (HBV/HDV) | Phase 1/2 | ~100% of near-term value — the only clinical asset |
| eVLP extrahepatic / HSPC editors | Preclinical/discovery | Optionality only; no sourceable value |
By geography (clinical-site footprint, not revenue): first-in-human sites are Hong Kong (first CTA), New Zealand, United Kingdom — deliberately non-US. The geographic "trend" that matters: a non-FDA-first footprint, which lowers cost/speed but raises the question of when (and on what data) a US IND follows (see Lens 13, Q13).
Trend / cause: the value mix has concentrated, not diversified — early Chroma pitched a broad multi-indication platform; capital pressure narrowed nChroma to one liver-led asset to data. Acceleration is binary on the late-2026 readout, not gradual.
Round history (all ``, unaudited):
| Date | Entity | Round | Amount | Lead(s) | Note |
|---|---|---|---|---|---|
| Oct 2021 | Chroma Medicine | Seed + Series A | $125M | Atlas, newpath, GV, Sofinnova, Casdin… | Launch out of stealth |
| early 2023 | Chroma Medicine | Series B | $135M | (existing syndicate) | Raised "amid industry turbulence" |
| Apr 2024 | Nvelop Therapeutics | Launch financing | $100M | (incl. ARCH) | Emerged from stealth |
| Dec 2024 | nChroma Bio (merge) | "Series A" reset | $75M | Cormorant, ARCH, Atlas, Newpath | Oversubscribed; concurrent with merger |
Cumulative capital into the two franchises ≈ $435M. The honest read: ~$360M had been spent or committed across Chroma + Nvelop before the merger, and the combined company chose to raise only $75M of fresh money — a down-sized reset, not an up-round.
The merger is a capital-allocation tell, not a triumph. Both companies cut staff (Chroma laid off in May 2024; the combined entity took "some reduction in the combined headcount" as "a necessary step"). Two well-funded startups fusing and shedding headcount in a hard biotech tape, raising a modest $75M, is the signature of capital scarcity forcing consolidation — the strong version of "1+1 = a better-funded shot," the weak version of "neither could raise a clean up-round alone." Reality is between, tilted toward necessity.
Pipeline by phase (+clinical — the asset table is the company):
| Program | Indication | Mechanism / modality | Delivery | Phase | Next readout |
|---|---|---|---|---|---|
| CRMA-1001 | Chronic hepatitis B (→ HBV/HDV coinfection) | dCas9 + epigenetic effector → targeted DNA methylation of cccDNA + integrated HBV DNA | LNP (liver) | Phase 1/2 (NCT07200193); first patient dosed 28 Jan 2026 | Clinical data anticipated late 2026 |
| Extrahepatic editors (undisclosed) | undisclosed (hepatic + extrahepatic) | epigenetic editors | eVLP (non-liver) | Preclinical / discovery | n/a — not disclosed |
| HSPC in-vivo targeting | undisclosed | epigenetic editing of hematopoietic stem cells | eVLP | Preclinical (ASGCT 2025 abstracts) | n/a — not disclosed |
Preclinical efficacy for CRMA-1001 (the data the whole bet rests on): in transgenic and AAV-HBV mouse models, >3-log reductions in HBsAg with durability extending 6 months; at the highest dose up to 90% of treated mice had undetectable HBsAg AND HBV DNA; non-human-primate studies showed sustained silencing >1 year post-dose. These are genuinely strong preclinical numbers — the question (Lens 12/13) is whether they translate to human cccDNA.
No earnings calls exist. The available "voice" is founder/exec commentary:
Sentiment trend: stable-to-constructive, low promotional quotient, milestones hit on time. The "things they stopped saying" tell: early-Chroma talked up a broad multi-indication platform; nChroma narrowed to HBV-first, liver-led, one asset to data — a healthy focusing, but also an admission that capital forces a single shot on goal.
Syndicate quality (the IPO-proximity read): unusually deep and crossover-heavy for a private at this stage. Tier-1 venture (ARCH, Atlas, Newpath, 5AM, Sofinnova, F-Prime, GV, DCVC Bio, Menlo, Omega, Casdin) plus dedicated crossover / public-markets funds: Cormorant (lead), T. Rowe Price, Wellington, Janus Henderson, Sixth Street, Mubadala, Alexandria. A Cormorant-led round with T. Rowe, Wellington and Janus Henderson on the line is a textbook IPO-syndicate-in-waiting — these are the names that mark a company and later anchor a crossover/IPO. But crossover presence ≠ imminence: they came in via the merger reset, the company is single-asset and pre-PoC, so the crossovers are a quality signal and an option, not a near-term S-1 trigger.
Valuation / secondary marks: n/a — private, not disclosed. PitchBook lists a profile but gates the figure behind a paywall; no public post-money or secondary mark is sourceable. Do not infer a number.
Mechanism comps (by target/modality, not P/E — this is the right comp axis for a clinical asset):
| Company | Lead asset | Modality | Indication | Clinical status (2026) | vs. nChroma |
|---|---|---|---|---|---|
| Tune Therapeutics | TUNE-401 | Epigenetic silencer (TEMPO), LNP | Chronic HBV | Phase 1b/2a PoC data (EASL, May 2026); Phase 2 late 2026 | ~12 months AHEAD, same mechanism, same indication |
| nChroma Bio | CRMA-1001 | Epigenetic silencer (dCas9), LNP | Chronic HBV/HDV | Phase 1/2, first dose Jan 2026; data late 2026 | — |
| GSK | Bepirovirsen | Antisense oligonucleotide | Chronic HBV | Phase 3; 19% functional cure | The incumbent-cure threat; redosing chronic |
| J&J (Janssen) | JNJ-3989 | siRNA | Chronic HBV | Mid/late clinical | "Lowers S antigen well"; chronic redose |
| Vir Biotechnology | VIR-2218 | siRNA | Chronic HBV | Clinical | chronic redose |
| Epic Bio | EPI-321 | Epigenetic editor (CasMINI) | FSHD (not HBV) | Dosing 2025 | Same modality, different disease |
| Omega Therapeutics | — | Epigenomic controllers | Oncology/other | distressed | modality peer, financially impaired |
The comp that matters is Tune, and it is unambiguously ahead with human data.
No public stock → "what moves the story" = milestones (the proxy for future stock-price catalysts once tradeable):
Pattern: the story reacts to (1) cash (can it survive) and (2) clinical de-risking (does the science work in humans). For a future IPO, the late-2026 PoC readout is the make-or-break print.
Capital-allocation history: mixed-to-pragmatic. The decision to merge and downsize rather than burn each company's cash chasing parallel programs was disciplined capital allocation under duress — but it is also an admission that prior capital (~$360M) bought less progress than hoped, and that neither standalone could raise a clean up-round. Insider ownership: not disclosed (private); founders/VCs hold, no figures sourceable. Skin in the game: founders are repeat company-builders with reputational capital staked.
Red flags (management): none of the classic forensic ones (no related-party deals, no promotional behavior, no excessive-comp disclosure — because nothing is disclosed). The honest yellow flag is strategic: serial financings and a restructuring-merger reveal a franchise that has consumed a lot of capital for a still-binary, pre-PoC asset.
Archetype: founder-scientist origin (Liu et al.) + professional-operator execution (Walsh/Marrazzo). For a clinical-stage company chasing a pharma exit, that is close to the ideal pairing — science credibility to make the asset, dealmaker credibility to sell it.
Forensic accounting: n/a — private, unaudited, no financial statements. There is no income statement, balance sheet, or cash-flow statement to forensically examine; no revenue recognition, SBC, goodwill, or receivables to interrogate. This is not a clean bill of health — it is the absence of disclosure, which is itself a risk: an outside investor is trusting the syndicate's diligence, not audited numbers.
Science & exclusivity (the +clinical re-point — this is where forensic scrutiny lands for a pre-revenue name):
Regulatory Findings (required sub-section):
There is no EPS to project (pre-revenue) and forecast.ts create is skipped per --watchlist rules. The two questions that actually matter for a private clinical-stage name:
(A) rNPV of the lead asset, CRMA-1001 (illustrative, every input ``):
(B) Runway-to-catalyst — the question that actually decides survival:
Brier forecast (the binary that matters, logged conceptually — not via forecast.ts per --watchlist):
CRMA-1001 demonstrates durable (off-treatment) HBsAg reduction in the Phase 1/2 readout by end-2027 — p ≈ 0.30.
Bull case. Epigenetic silencing is the most credible path to a one-dose functional cure for a 254M-patient chronic disease — and Tune's May-2026 human data just de-risked the entire modality (100% biomarker repression at dose levels 2–4, durable to 17 months). That is a gift to nChroma: it proves the mechanism works in humans before nChroma's own readout, converting nChroma from "will the modality work?" to "is nChroma's editor as good as Tune's?" — a far better question to be asking. nChroma brings (a) arguably superior IP/founding science (the Liu/Joung/Weissman cluster, dual cccDNA + integrated-DNA targeting), (b) a chairman (Marrazzo) who has run the exact gene-therapy build-to-$4.8B-exit playbook, (c) a crossover-heavy syndicate (Cormorant, T. Rowe, Wellington) primed to fund an IPO, and (d) a second act — the eVLP extrahepatic delivery platform — that is an option no pure HBV play has. A clean late-2026 readout makes nChroma a prime M&A target or a 2027 IPO candidate.
Bear case (2–3 permanent-impairment risks).
Pre-mortem (18 months out, thesis broke): the late-2026 readout showed strong on-treatment HBsAg knockdown but the effect waned after dosing stopped — exactly the reversal the literature warned of. Simultaneously Tune's larger Phase 2 confirmed durable cure, locking up the marquee pharma partner. nChroma, cash-thin, raised a punishing down-round and pivoted to the eVLP platform as the surviving story.
Are the multiples too high? No public multiple exists. The implied private value is dominated by the binary readout; "too high / too low" is unknowable until the data prints. n/a.
Contrarian view (what the market refuses to see): consensus frames nChroma as the also-ran to Tune. The contrarian read is that Tune's success is nChroma's call option — modality validation is the hardest gate in biotech, and Tune just paid for it. If nChroma's dual-targeting editor matches Tune's durability, a ~12-month lag is trivial in a market this large and this underserved, and nChroma's superior delivery platform + Marrazzo-grade dealmaking could make it the better-packaged acquisition. Second place in a validated, enormous market is a far better place to stand than first place in an unproven one.
Dismantling the bull case:
A founder-led rare-disease engine with real ($673M) revenue and a pioneer at the helm — but it just lost its biggest pipeline bet (setrusumab) and is burning ~$466M/yr against ~$534M cash, so the entire equity now rides on two H2-2026 FDA approvals (UX111 Sep 19, DTX401 Aug 23) closing the gap to a promised 2027 profit. Binary, not compounding.
A real RNA-medicine platform finally turning into a P&L — but the stock is a pelacarsen option with seven launches as the floor. Own the platform, size for the binary.
A profitable liquid-biopsy oncology franchise quietly cross-subsidising a binary, USPSTF-gated bet on blood-based cancer screening — the re-rating from $52 to $130 already paid for the Shield optionality, so from here you are paying ~11x sales to be long a single 2026 guideline decision.